Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4398 | 1717 | 46.3 | 90% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
40 | 31853 | AIDS RESEARCH AND HUMAN RETROVIRUSES//HIV 1//AIDS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | HIV LATENCY | Author keyword | 57 | 78% | 2% | 38 |
2 | HIV CURE | Author keyword | 25 | 65% | 1% | 24 |
3 | HIV 1 LATENCY | Author keyword | 22 | 67% | 1% | 20 |
4 | RESTING CD4 T CELLS | Author keyword | 21 | 90% | 1% | 9 |
5 | HIV PERSISTENCE | Author keyword | 21 | 85% | 1% | 11 |
6 | HIV RESERVOIR | Author keyword | 20 | 59% | 1% | 23 |
7 | TREATMENT INTERRUPTION | Author keyword | 16 | 32% | 2% | 42 |
8 | HIV 1 DNA | Author keyword | 14 | 51% | 1% | 19 |
9 | HIV RESERVOIRS | Author keyword | 14 | 57% | 1% | 16 |
10 | VIRAL RESERVOIRS | Author keyword | 13 | 55% | 1% | 16 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HIV LATENCY | 57 | 78% | 2% | 38 | Search HIV+LATENCY | Search HIV+LATENCY |
2 | HIV CURE | 25 | 65% | 1% | 24 | Search HIV+CURE | Search HIV+CURE |
3 | HIV 1 LATENCY | 22 | 67% | 1% | 20 | Search HIV+1+LATENCY | Search HIV+1+LATENCY |
4 | RESTING CD4 T CELLS | 21 | 90% | 1% | 9 | Search RESTING+CD4+T+CELLS | Search RESTING+CD4+T+CELLS |
5 | HIV PERSISTENCE | 21 | 85% | 1% | 11 | Search HIV+PERSISTENCE | Search HIV+PERSISTENCE |
6 | HIV RESERVOIR | 20 | 59% | 1% | 23 | Search HIV+RESERVOIR | Search HIV+RESERVOIR |
7 | TREATMENT INTERRUPTION | 16 | 32% | 2% | 42 | Search TREATMENT+INTERRUPTION | Search TREATMENT+INTERRUPTION |
8 | HIV 1 DNA | 14 | 51% | 1% | 19 | Search HIV+1+DNA | Search HIV+1+DNA |
9 | HIV RESERVOIRS | 14 | 57% | 1% | 16 | Search HIV+RESERVOIRS | Search HIV+RESERVOIRS |
10 | VIRAL RESERVOIRS | 13 | 55% | 1% | 16 | Search VIRAL+RESERVOIRS | Search VIRAL+RESERVOIRS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LATENT RESERVOIR | 193 | 70% | 9% | 159 |
2 | POSTINTEGRATION LATENCY | 73 | 85% | 2% | 39 |
3 | LIFELONG PERSISTENCE | 65 | 84% | 2% | 36 |
4 | PLASMA VIREMIA | 57 | 43% | 6% | 101 |
5 | RALTEGRAVIR INTENSIFICATION | 52 | 65% | 3% | 49 |
6 | LOW LEVEL VIREMIA | 45 | 46% | 4% | 72 |
7 | INTERMITTENT VIREMIA | 36 | 79% | 1% | 23 |
8 | STRUCTURED TREATMENT INTERRUPTIONS | 33 | 38% | 4% | 71 |
9 | VIRAL RESERVOIRS | 31 | 61% | 2% | 33 |
10 | SCHEDULED TREATMENT INTERRUPTIONS | 30 | 84% | 1% | 16 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? | 2015 | 4 | 36 | 72% |
The Challenge of Finding a Cure for HIV Infection | 2009 | 350 | 41 | 71% |
Towards an HIV-1 cure: measuring the latent reservoir | 2015 | 2 | 102 | 77% |
Understanding HIV Latency: The Road to an HIV Cure | 2015 | 3 | 92 | 53% |
Emerging strategies to deplete the HIV reservoir | 2014 | 22 | 38 | 71% |
Redefining the Viral Reservoirs that Prevent HIV-1 Eradication | 2012 | 96 | 136 | 54% |
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs | 2013 | 57 | 103 | 51% |
Changes in HIV reservoirs during long-term antiretroviral therapy | 2015 | 1 | 57 | 93% |
Experimental approaches to the study of HIV-1 latency | 2007 | 117 | 107 | 63% |
HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals | 2010 | 131 | 71 | 45% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLIN EAR NOSE THROAT SURG | 4 | 75% | 0.2% | 3 |
2 | IUT LOUIS PASTEUR ILTIGHEIM | 4 | 75% | 0.2% | 3 |
3 | PATHOGENIE INFECT LENTIVIRUS | 4 | 75% | 0.2% | 3 |
4 | SERV MOL VIROL | 4 | 75% | 0.2% | 3 |
5 | MICHAEL HOOKER 3302 | 3 | 100% | 0.2% | 3 |
6 | BBRB | 3 | 60% | 0.2% | 3 |
7 | EYKMAN WINKLER | 2 | 67% | 0.1% | 2 |
8 | INT PHD MOL MED | 2 | 67% | 0.1% | 2 |
9 | RIGHT | 2 | 33% | 0.3% | 5 |
10 | DIAGNOST VACCINOL | 2 | 24% | 0.4% | 7 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000158988 | IMMUNE RECONSTITUTION//CLIN MOL RETROVIROL SECT//IMMUNE ACTIVATION |
2 | 0.0000149353 | INTRACELLULAR DELAY//VIRUS DYNAMICS//HIV DYNAMICS |
3 | 0.0000126098 | ROYAL FREE HIV MED//CD4 CELL COUNT//X BICHAT MED |
4 | 0.0000108533 | UNITE RETROVIROL MOL//ENTROPY EVOLUTION RATE//HIV 1 MOTHER TO CHILD TRANSMISSION |
5 | 0.0000097445 | PARTNERS AIDS//HIV PATHOGENESIS PROGRAMME//DORIS DUKE MED |
6 | 0.0000089587 | K65R//TRANSMITTED DRUG RESISTANCE//HIV 1 DRUG RESISTANCE |
7 | 0.0000087468 | MICROBIAL TRANSLOCATION//HIV ENTEROPATHY//ISOSPORA BELLI |
8 | 0.0000082361 | SERV REG MALAD INFECT//EQUIPE INTERFERON CYTOKINES//PHARMA NEW TECHNOL |
9 | 0.0000080790 | DOUBLE POSITIVE T CELLS//CD4CD8 T CELLS//CD8 INFECTION |
10 | 0.0000080200 | TAT//TAT PROTEIN//TAR RNA |